Cytokinetics, Inc. (CYTK) EVP Fady Ibraham Malik Sells 1,500 Shares

Share on StockTwits

Cytokinetics, Inc. (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 1,500 shares of the stock in a transaction dated Thursday, December 6th. The stock was sold at an average price of $7.38, for a total value of $11,070.00. Following the sale, the executive vice president now owns 87,067 shares of the company’s stock, valued at approximately $642,554.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Fady Ibraham Malik also recently made the following trade(s):

  • On Thursday, November 1st, Fady Ibraham Malik sold 1,500 shares of Cytokinetics stock. The stock was sold at an average price of $6.68, for a total value of $10,020.00.
  • On Thursday, October 4th, Fady Ibraham Malik sold 1,500 shares of Cytokinetics stock. The stock was sold at an average price of $9.14, for a total value of $13,710.00.

Shares of NASDAQ:CYTK traded down $0.17 during trading on Friday, hitting $7.40. 287,489 shares of the company’s stock were exchanged, compared to its average volume of 338,293. The company has a current ratio of 10.57, a quick ratio of 10.58 and a debt-to-equity ratio of 0.73. Cytokinetics, Inc. has a 52-week low of $6.02 and a 52-week high of $10.26.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.11. The firm had revenue of $10.64 million for the quarter, compared to the consensus estimate of $2.23 million. On average, equities research analysts anticipate that Cytokinetics, Inc. will post -1.96 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in CYTK. BlackRock Inc. boosted its stake in Cytokinetics by 9.5% during the third quarter. BlackRock Inc. now owns 8,698,387 shares of the biopharmaceutical company’s stock valued at $85,680,000 after buying an additional 754,593 shares during the last quarter. Millennium Management LLC boosted its stake in Cytokinetics by 351.9% during the second quarter. Millennium Management LLC now owns 461,733 shares of the biopharmaceutical company’s stock valued at $3,832,000 after buying an additional 359,561 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Cytokinetics by 233.6% during the third quarter. Dimensional Fund Advisors LP now owns 229,377 shares of the biopharmaceutical company’s stock valued at $2,259,000 after buying an additional 160,622 shares during the last quarter. Marshall Wace North America L.P. bought a new position in Cytokinetics during the third quarter valued at approximately $1,291,000. Finally, Northern Trust Corp boosted its stake in Cytokinetics by 16.7% during the second quarter. Northern Trust Corp now owns 498,546 shares of the biopharmaceutical company’s stock valued at $4,138,000 after buying an additional 71,418 shares during the last quarter. 70.47% of the stock is owned by institutional investors.

Several analysts recently issued reports on the company. ValuEngine upgraded Cytokinetics from a “hold” rating to a “buy” rating in a research report on Wednesday, October 3rd. BidaskClub upgraded Cytokinetics from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 28th. HC Wainwright set a $21.00 target price on Cytokinetics and gave the stock a “buy” rating in a research report on Friday, November 2nd. Morgan Stanley assumed coverage on Cytokinetics in a research report on Monday, September 10th. They set an “equal weight” rating and a $10.00 target price for the company. Finally, Zacks Investment Research upgraded Cytokinetics from a “sell” rating to a “hold” rating and set a $8.00 target price for the company in a research report on Friday, November 2nd. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Cytokinetics currently has an average rating of “Buy” and an average price target of $12.83.

ILLEGAL ACTIVITY WARNING: “Cytokinetics, Inc. (CYTK) EVP Fady Ibraham Malik Sells 1,500 Shares” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4001082/cytokinetics-inc-cytk-evp-fady-ibraham-malik-sells-1500-shares.html.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

See Also: What is a Derivative?

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

UBS Group Reaffirms Buy Rating for BP
UBS Group Reaffirms Buy Rating for BP
888 Holdings Public  Rating Reiterated by Peel Hunt
888 Holdings Public Rating Reiterated by Peel Hunt
Peel Hunt Lowers Berkeley Group  to Add
Peel Hunt Lowers Berkeley Group to Add
Comparing Seven Stars Cloud Group  and SoOum
Comparing Seven Stars Cloud Group and SoOum
Short Interest in Asanko Gold Inc  Grows By 15.8%
Short Interest in Asanko Gold Inc Grows By 15.8%
Avacta Group  Given Corporate Rating at FinnCap
Avacta Group Given Corporate Rating at FinnCap


Leave a Reply

© 2006-2018 Ticker Report